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Background: Fibroadenomas are benign human breast tumors, characterized by proliferation of epithelial and
stromal components of the terminal ductal unit. They may grow, regress or remain unchanged, as the hormonal
environment of the patient changes. Expression of antigen TF in mucin or mucin-type glycoproteins and of
galectin-3 seems to contribute to proliferation and transformations events; their expression has been reported in
ductal breast cancer and in aggressive tumors.
Findings: Lectin histochemistry, immunohistochemistry, and immunofluorescence were used to examine the
expression and distribution of antigen TF and galectin-3. We used lectins from Arachis hypogaea, Artocarpus
integrifolia, and Amaranthus lecuocarpus to evaluate TF expression and a monoclonal antibody to evaluate
galectin-3 expression. We used paraffin-embedded blocks from 10 breast tissues diagnosed with fibroadenoma and
as control 10 healthy tissue samples. Histochemical and immunofluorescence analysis showed positive expression
of galectin-3 in fibroadenoma tissue, mainly in stroma, weak interaction in ducts was observed; whereas, in healthy
tissue samples the staining was also weak in ducts. Lectins from A. leucocarpus and A. integrifolia specificaly
recognized ducts in healthy breast samples, whereas the lectin from A. hypogaea recognized ducts and stroma. In
fibroadenoma tissue, the lectins from A. integrifolia, A. Hypogaea, and A. leucocarpus recognized mainly ducts.
Conclusions: Our results suggest that expression of antigen TF and galectin-3 seems to participate in
fibroadenoma development.
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Fibroadenomas are benign breast tumors commonly
found in young women. Fibroadenoma is a biphasic lesion
of the breast characterized by proliferation of both epithe-
lial and stromal components of the terminal ductal unit.
Proliferation of stromal cells is commonly considered the
primary event in the development of a fibroadenoma, fol-
lowed by secondary proliferation of epithelial cells [1].
Most fibroadenomas are considered to be the result of
hyperplastic processes involving connective tissue of lobu-
lar units [2]. Fibroadenomas’ development is heteroge-
neous, since they may grow, regress, or remain unchanged
as the hormonal environment ofthe patient changes, but* Correspondence: fuegoblanco136@yahoo.com.mx
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reproduction in any medium, provided the ormost stop growing after reaching 2 to 3 cm in diameter
[3], moreover, with aging, the stroma becomes less cellular
and increases its hyalinization [4]. Occurrence in young
women and sclerotic involution in the elderly suggest a
hormonal responsiveness of fibroadenomas [1].
O-glycosylation plays an important role in the bio-
logical activity of glycoproteins involved in controlling
cell differentiation [5,6]. Alterations in glycosylation of
cell membrane glycocongugates in neoplastic lesions
from a variety of organs, including lung, stomach,
ovary, skin and endometrium, have been reported [7,8].
Abnormal O-glycosylation, especially in mucin and
mucin type glyproteins, results in exposure of the peptide
core, as well as in the exposure of the normally cryptic
core TF (Galβ1-3GalNAcα1-O-Ser/Thr) antigen [9], which
is distributed discontinuously along the peptide backbone,
and premature sialylation can occur leading to formation
of antigens related to cancer progression [10].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Interaction of lectin or antibodies with all the
healthy and fibroadenoma breast samples* used in this
study
ANTIBODY NORMAL FIBROADENOMA
+ - + -
Anti galectin-3 10 0 10 0
Arachis hypogaea 10 0 10 0
Artocarpus integrifolia 6 4 8 2
Amaranthus leucocarpus 6 4 8 2
N = 10 healthy and 10 fibroadenoma samples evaluated.
Table 2 Staining of normal and fibroadenoma using anti-
galectin-3 antibody and lectins*
ANTIBODY NORMAL FIBROADENOMA
Anti-Galectin-3 1 2
Arachis hypogaea 2 1
Artocarpus integrifolia 1 1
Amaranthus leucocarpus 1 2
*The presence and absence of staining in breast samples was recorded as
follows: No stain, 0; ductal stain, 1; ductal and estromal stain, 2.
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precipitate glycoconjugates and they are important tools
for oligosaccharide characterization as well as for isola-
tion of cellular populations [11]. Galectin-3 is a 31 kDa
protein member of the beta-galactoside-binding pro-
teins; it is an intracellular and extracellular lectin that
interacts with intracellular glycoproteins, cell surface
molecules, and extracellular matrix proteins. Galectin-3
is expressed widely in epithelial and immune cells and
its expression is correlated with cancer aggressiveness
and metastasis [12]. The aim of this study was to deter-
mine, by histochemsitry, the over-expression of antigen
TF and galectin-3 in fibroadenoma and healthy breast
tissues, using specific lectins for antigen TF and anti-
galectin-3 antibody, to understand better the potential
role of O-glycosylation in fibroadenomas’ progression.
Findings
Reagents
Biotynilated lectins from Arachis hypogaea and Artocarpus
integrifolia were obtained from Vector Laboratories
(Burlingame, CA USA). Lectin from Amaranthus
leucocarpus (ALL) was purified by affinity chromatog-
raphy using a column containing stroma from human
O-desialylated erythrocytes entrapped in Sephadex G-25
(Upssula Sweden), as described previously [13]. ALL was
labeled with the N-hydroxisuccinimide ester of biotin
(Bio-Rad Inc., Richmond, CA, USA) at a label/protein
ratio of 2:1 [14] Avidin-peroxidase, sugars, and chemical
reagents were from (Sigma Chemical Co, St. Louis, MO,
USA), 3-amino-9-ethyl-carbazole (AEC) kit used as sub-
strate for peroxidase was obtained from Vector Laborator-
ies. Biotin-labeled mouse anti-galectin-3 was obtained
from Invitrogen (Carlsbad, CA USA).
Source of tissues
Ten paraffin-embedded blocks from breast tissues diag-
nosed with fibroadenoma were kindly donated by Paulina
Leyva, from the Pathology Department of the School of
Medicine, UABJO, Oaxaca, Mexico. Ten healthy control
tissue samples were obtained from cosmetic procedures at
the Plastic Surgery service from the Mexican Institute of
Social Security (IMSS, for its initials in Spanish), Mexico.
Ethical approval
The study protocol was approved by the Institutional
Review Board of Research of the Medical School of
UABJO.
Immunohistochemistry
Paraffin-embedded blocks from fibroadenoma and nor-
mal breast tissues, the latter used as controls, were cut
in 6-μm-thick sections. Sections were incubated with
each biotin-labeled lectin (1 μg/ml) or monoclonal anti-galectin-3 antibody (dilution 1:100), overnight at 4°C.
After incubation, the slides were washed with PBS, pH
7.4, and covered with 300 μl of 5% skimmed milk in
PBS, pH 7.4, and incubated for 12 h at 4°C. Then, after
washing with PBS, pH 7.4, the samples were labeled with
streptavidin-peroxidase (1:1000 in PBS) for 1 h at 37°C.
Unbound conjugate was removed by washing six times
with PBS. The binding of lectins or antibody was revealed
by incubating with 3-amino-9-ethyl-carbazole (AEC), fol-
lowing instructions of manufacturer (Invitrogen), during
15 min at 37°C. The reaction was stopped by washing with
water. Slides were observed with an AXIOSCOP 40
microscope (Zeiss, Germany) equipped with a digital
camera AXIOCAM MRC (Zeiss) and micrographs were
analyzed with the AXIOVISION 4.3 Software (Zeiss).Immunofluorescence
Double labeling of slides was performed as follows:
Tissue samples were labeled with lectins (1 μg/ml) over-
night at 4°C and monoclonal anti-galectin-3 antibody
used at 1:100 following the same procedure as previously
described, except that lectin binding was indirectly
recognized with extravidin-FITC conjugated (Sigma
Chemical Co.) and visualized using a green filter.
Anti-galectin antibodies were revealed with extravidin-
red-X conjugate (Invitrogen) and visualized using a red fil-
ter. Slides were observed with an AXIOSCOP 40 micro-
scope (Zeiss), equipped with a digital camera AXIOCAM
MRC (Zeiss) and micrographs were analyzed with the
AXIOVISION 4.3 Software (Zeiss).
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Figure 1 Lectin and anti-galectin-3 histochemistry in healthy breast and fibroadenoma samples. Amaranthus leucocarpus recognizes ducts
in healthy breast samples (A1): in fibroadenoma, Amaranthus leucocarpus lectin recognizes ducts and stroma cells (A2). Artocarpus integrifolia
lectin recognizes ducts in healthy (B1) and fibroadenoma samples (B2). Arachis hypogaea recognizes ducts in healthy (C1) and in fibroadenoma
samples (C2). Anti-galectin-3 antibody depicts weak staining in ducts of healthy samples (D1); in fibroadenoma, the antibody recognizes ducts
and stroma cells (D2) Arrows indicate the lectin and antibody binding sites. Black arrow indicates ducts site of lectin or antibody binding. Yellow
arrow indicates stroma site of lectin or antibody binding. Micrographs are in 10X.









Figure 2 Lectin and anti-galectin-3 double labeling histochemistry, in healthy breast and fibroadenoma samples. Weak staining with
anti-galectin-3 was observed in healthy samples (A). Artocarpus integrifolia lectin recognizes ducts and stroma in healthy breast samples (B1).
Arachis hypogaea recognizes ducts and stroma in healthy samples (C1). Amaranthus leucocarpus recognizes ducts and stroma in healthy breast
samples (D1). In fibroadenoma, anti-galectin-3 recognizes ducts and stroma (B2) (C2) (D2). White arrow indicates ducts site of lectin or antibody
binding. Yellow arrow indicates stroma site of lectin or antibody binding. Micrographs 10X.
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To determinate the lectins’ specificity in control breast
epithelium and fibroadenomas, lectin histochemistry and
immunoflourescence assays were performed using lec-
tins incubated with 200 mM of their specific monosac-
charide (N-acetyl-D-galactosamine) 30 min before use.
Statistical analysis
Fisher’s exact test using Woolf ’s approximation was per-
formed using GraphPad InStat version 3.00, GraphPad
Software, San Diego California USA.
Results
Lectins and anti galectin-3 histochemistry
Numbers of samples positive and negative to either lec-
tins or antibody are summarized in Table 1. As indicated
in Table 2, in control samples, obtained from healthy tis-
sues. Amaranthus leucocarpus lectin (ALL) recognized
ducts in healthy breast samples (Figure 1. A1); whereas,
in fibroadenoma tissues, this lectin recognized ducts and
stroma cells (Figure 1. A2). A. integrifolia lectin recog-
nized ducts in healthy (Figure 1. B1) and fibroadenoma
samples equally well (Figure 1. B2). A. hypogaea recog-
nized ducts in healthy (Figure 1. C1) and fibroadenoma
samples (Figure 1. C2). Anti-galectin-3 antibody showed
a weak staining in ducts of healthy samples (Figure 1. D1);
however, in fibroadenoma tissue, the antibody recognized
ducts and stroma cells (Figure 1. D2).
Immunofluorescence
Lectins and anti-galectin-3, in double labeling immuno-
flourescence, in healthy breast and fibroadenoma sam-
ples, showed weak staining with anti-galectin-3 in
healthy samples (Figure 2. A). A. integrifolia lectin recog-
nized ducts and stroma in healthy (Figure 2. B1) and in
fibroadenoma samples; whereas antigalectin-3 recognized
ducts and stroma (Figure 2. B2). A. hypogaea recognized
ducts and stroma in healthy samples (Figure 2. C1);A1
Figure 3 Lectin and anti-galectin-3 double labeling histochemistry in
luminal cells of ducts (A1). No interaction with luminal cells was observed
site of lectin or antibody binding. Micrographs (40X).whereas, in fibroadenoma samples, anti-galectin-3 recog-
nized ducts and stroma (Figure 2. C2). Amaranthus
leucocarpus recognized ducts and stroma in healthy breast
samples (Figure 2. D1); in fibroadenoma samples, anti-
galectin-3 recognized ducts and stroma (Figure 2. D2).
A. integrifolia lectin recognized luminal cells of ducts in
fibroadenoma (Figure 3. A1). No interaction with luminal
cells was observed in fibroadenomas using anti-galectin-3
antibody (Figure 3. A2). Lectins and anti-galectin-3 anti-
body staining showed no co-localization.
Statistical results
Lectins and using anti-galectin-3 antibody were not sta-
tistically significant
Discussion
A fibroadenoma is a benign tumor with stromal and epi-
thelial elements [15,16]; however, it has been associated
with increased risk for breast cancer, particularly when
associated with fibrocystic changes, proliferative breast
disease, or a family history of breast cancer [17]. Recently,
studies in alterations of the membrane’s protein glycosyla-
tion have been performed to understand better the
changes taking place during cellular transformation to
cancer [18,19]. Lectins, due to their higher specificity for
carbohydrates and glycoconjugates, have been used to
detect glycosylation changes in cancer cells [20-22]. In
this work, we studied the glycosylation pattern in fibro-
adenomas using lectins with specificity for N-acetyl-D-
galactosamine linked to protein or lipids. In fibroadenoma
samples, lectins recognized different cytoplasmic regions
from those recognized by antibodies, indicating that some
cells express mucin-type O-glycans. In dermal carcinoma,
as well as in carcinoma in situ [23], Arachis hypogaea,
Artocarpus integrifolia, and Amaranthus leucocarpus
lectins recognize the Galβ1-3GalNAc or TF antigen
(Thomsen-Friedenreich antigen). Our results showed that
the A. leucocarpus lectin recognized ducts in controlA2
fibroadenoma samples. Artocarpus integrifolia lectin recognizes
in fibroadenoma using anti-galectin-3 (A2). White arrow indicates ducts
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and some stromal cells. The recognition pattern of Arachis
hypogaea was the same in control and fibroadenoma
tissues, i.e., the lectin recognized ducts. A. intergrifolia
recognized ducts in control samples, but in fibroadenoma
the lectin recognized luminal cells. The ability of lectins to
bind carbohydrates depends on their 3-D structure [24,25]
and on their capacity to detect subtle variations in the con-
formation of carbohydrate structures of cell surfaces [25].
This ability could be explained by the variability in the size
of the carbohydrate-recognition domain (CDR) and the
variability in quaternary association [25]. Interestingly, the
CDR of A. leucocarpus lectin recognizes GalNAc residues
when they are spaced out in glycan structures, whereas
GalNAc residues arranged in clusters prevent interaction
with the lectin [26]. These glycans have been related with
cervical cancer development [27] and are present in fibro-
adenomas [28], whereas Artocarpus integrifolia lectin can
recognize clusters of TF antigen.
Galectin-3 is a naturally occurring galactoside-binding
lectin expressed intra- and extra-cellularly by many cell
types [29]. It has been shown that galectin-3 expression
is increased in patients with breast, gastrointestinal, or
lung cancer [30]. Moreover, higher galectin-3 expression
has been shown in patients with metastatic disease than
in patients with localized tumors [31]. Cytoplasmic
galectin-3 is known to be anti-apoptotic, whereas nu-
clear galectin-3 promotes pre-mRNA splicing [32]. Cell
surface galectin-3 is involved in various cell-cell and
cell-matrix interactions [33,34] and enhances cancer cell
adhesion and invasion through basement membrane by
interacting with extracellular matrix proteins such as
fibronectin, collagen, or laminin [35,36]. Galectin-3
expressed on the endothelial cell surface has been shown
to promote adhesion of breast cancer cells to the
endothelium by interaction with cancer- associated
Thomsen-Friedenreich antigen cell surface molecules
[37,38]. TF antigen is the core I structure of mucin-type
O-linked glycans, but in its simplest nonsialylated form,
as non-extended form it acts as an oncofetal antigen,
and its presence/expression is increased in malignant
and premalignant epithelia [39,40]. A weak interaction
with ducts, in healthy samples was observed when anti-
galectin-3 antibody was used, whereas, in fibroadenoma
samples, the interaction was observed in ducts and
stromal cells.Conclusions
Our results suggest that galectin-3 and Galß1,3-GalNAC
glycosylated glycoproteins represent important elements
in fibroadenomas’ development, reinforcing the notion
that lectins constitute a very useful tool for the study of
breast cancer.Abbreviations
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